Skip to main
ORGO
ORGO logo

Organogenesis Holdings (ORGO) Stock Forecast & Price Target

Organogenesis Holdings (ORGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Organogenesis Holdings Inc. is strategically positioned to benefit from an anticipated improvement in valuation as it navigates the mixed performance influenced by market dynamics and impending reimbursement changes in the advanced wound care segment. The company's ability to generate solid operating profits is expected to enhance its market share, particularly as reimbursement rates are set to rise slightly in 2026. Additionally, with a comprehensive product portfolio and significant growth opportunities in underpenetrated markets, Organogenesis Holdings is poised for a favorable trajectory in the regenerative medicine sector.

Bears say

Organogenesis Holdings Inc faces a negative outlook primarily due to significant risks related to lower-than-expected growth of its PuraPly product line, potential adverse impacts from Medicare Part B pricing on amniotic products, and challenges posed by competitive pressures that may hinder market share gains. Additionally, the company might encounter difficulties from Medicare Administrative Contractors and a slower uptake of new products, compounded by negative clinical data outcomes that could undermine market confidence. Financially, the company's investment in the ReNu program has accrued substantial costs of approximately $30 million for FY24, pushing back potential clearance timelines and reflecting the ongoing burden of increasing research and development expenditures without a corresponding improvement in revenue prospects.

Organogenesis Holdings (ORGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Organogenesis Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Organogenesis Holdings (ORGO) Forecast

Analysts have given Organogenesis Holdings (ORGO) a Buy based on their latest research and market trends.

According to 3 analysts, Organogenesis Holdings (ORGO) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Organogenesis Holdings (ORGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.